Last reviewed · How we verify

I.V. palonosetron — Competitive Intelligence Brief

I.V. palonosetron (I.V. palonosetron) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: 5-HT3 receptor antagonist. Area: Oncology.

phase 3 5-HT3 receptor antagonist 5-HT3 receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

I.V. palonosetron (I.V. palonosetron) — Helsinn Healthcare SA. Palonosetron is a selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
I.V. palonosetron TARGET I.V. palonosetron Helsinn Healthcare SA phase 3 5-HT3 receptor antagonist 5-HT3 receptor
Trintellix vortioxetine Takeda marketed Serotonin modulator and stimulator (SMS); SSRI-like agent Serotonin transporter (SERT); 5-HT3 receptor; 5-HT1A receptor 2013-01-01
Sodium Bicarbonate Powder and ondansetron Sodium Bicarbonate Powder and ondansetron Aya Sabry Mohamed Mohamed marketed Antacid and antiemetic combination 5-HT3 receptor (ondansetron); non-specific acid neutralization (sodium bicarbonate)
Metoclopramide, Granisetron, or Ondansetron Metoclopramide, Granisetron, or Ondansetron Sanofi marketed Antiemetic agents (dopamine antagonist, 5-HT3 receptor antagonists) Dopamine receptors (metoclopramide); 5-HT3 receptors (granisetron, ondansetron)
Akynzeo solution Akynzeo solution Helsinn Healthcare SA marketed NK1 receptor antagonist / 5-HT3 receptor antagonist combination NK1 receptor (netupitant component); 5-HT3 receptor (palonosetron component)
Dexamethasone and ondansetron Dexamethasone and ondansetron Yeditepe University Hospital marketed Corticosteroid + 5-HT3 receptor antagonist combination Glucocorticoid receptor (dexamethasone); 5-HT3 receptor (ondansetron)
cardiac output changes with "ondansetron" cardiac output changes with "ondansetron" University Tunis El Manar marketed 5-HT3 receptor antagonist 5-HT3 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (5-HT3 receptor antagonist class)

  1. Helsinn Healthcare SA · 4 drugs in this class
  2. LG Life Sciences · 3 drugs in this class
  3. University of Malaya · 2 drugs in this class
  4. GlaxoSmithKline · 1 drug in this class
  5. Hamad Medical Corporation · 1 drug in this class
  6. Eye & ENT Hospital of Fudan University · 1 drug in this class
  7. Instituto Mexicano del Seguro Social · 1 drug in this class
  8. Chongqing University Cancer Hospital · 1 drug in this class
  9. Merck Sharp & Dohme LLC · 1 drug in this class
  10. MonoSol Rx · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). I.V. palonosetron — Competitive Intelligence Brief. https://druglandscape.com/ci/i-v-palonosetron. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: